A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B

A Two-arm, Open-label, Single-sequence, Multiple-dose Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B in Healthy Adult Volunteers

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07730567

Enrollment

Registered

2026-07-28

Start date

2026-07-29

Completion date

2026-09-26

Last updated

2026-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabete Type 2, Hyperlipidemia

Brief summary

To evaluate the pharmacokinetic interaction and the safety of AD-236A and AD-236B in healthy adult volunteers

Interventions

DRUGTreatment A(AD-236A)

AD-236A Oral Tablet

DRUGTreatment B(AD-236B)

AD-236B Oral Tablet

DRUGTreatment C(AD-236A+AD-236B)

AD-236A+AD-236B Oral Tablet

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy adult volunteers aged ≥19 and ≤55 years at the time of the screening visit * Body weight ≥50 kg (≥45 kg for females) and body mass index (BMI) between 18.0 kg/m² and 30.0 kg/m² at the time of the screening visit

Exclusion criteria

* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration * Other exclusions applied

Design outcomes

Primary

Measure	Time frame	Description
1. Area under the plasma concentration-time curve during dosing interval at steady state (AUCτ,ss)	pre-dose (0hour) to 24 hours post-dose	AUCτ,ss
Maximum concentration of drug in plasma at steady state (Cmax,ss)	pre-dose (0hour) to 24 hours post-dose	Cmax,ss

Countries

South Korea

Contacts

CONTACTHeeyoung Hong

hyhong@addpharma.co.kr821094710619

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 29, 2026